TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Feature|Articles|September 23, 2026
Shaping the Future of Market Access: Q&A with Jen Norton
Author(s)Jen Norton
Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Advertisement
Advertisement
How to help drug manufacturers navigate complex market factors to reach more patients is a challenge nearly every company faces. That’s why market access strategies continue to be top of mind in the industry. Recently, Pharmaceutical Executive caught up with Jen Norton, a veteran in market access who recently joined EVERSANA.
Related to this article
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
Advertisement
Advertisement